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Background: NADH:ubiquinone oxidoreductase (complex I) is the ¢rst of three
large enzyme complexes located in the cell's inner mitochondrial membrane
which form the electron transport chain that carries electrons from NADH to
molecular oxygen during oxidative phosphorylation. There is signi¢cant interest in
developing small molecule inhibitors of this enzyme for use as biological probes,
insecticides and potential chemopreventive/chemotherapeutic agents. Herein we
describe the application of novel natural product-like libraries to the discovery of a
family of potent benzopyran-based inhibitors.
Results: Initially a combinatorial library of benzopyrans, modeled after natural
products, was synthesized using a solid phase cycloloading strategy. Screening
of this diversity oriented library for inhibitory potency against NADH:ubiquinone
oxidoreductase activity in vitro using bovine heart electron transport particles
provided several lead compounds which were further re¢ned through a series of
focused libraries.
Conclusions: Using this combinatorial library approach, a family of potent 2,2-
dimethylbenzopyran-based inhibitors was developed with IC50 values in the range
of 18^55 nM. Cell-based assays revealed that these inhibitors were rather non-
cytotoxic in the MCF-7 cell line; however, they were quite cytostatic in a panel of
cancer cell lines suggesting their potential as chemotherapeutic/chemopreventive
candidates.
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Introduction
NADH:ubiquinone oxidoreductase (complex I) is the ¢rst
of three large enzyme complexes located in the inner mi-
tochondrial membrane which form the electron transport
chain that carries electrons from NADH to molecular oxy-
gen during oxidative phosphorylation (Figure 1) [1]. Com-
plex I is the most intricate enzyme known, consisting of
over 40 individual protein sub-units with one non-cova-
lently bound £avin mononucleotide and at least ¢ve
iron^sulfur clusters. This enzyme serves an essential role
Figure 1. Role of NADH:ubiquinone oxidoreductase (complex I) on oxidative phosphorylation.
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in cellular physiology such that structural or functional de-
¢ciencies in it have been implicated in the pathogenesis of
diseases such as Parkinson’s, focal dystonia and Leber’s
hereditary optic neuropathy [2].
A variety of natural and synthetic inhibitors of complex I
(see representative examples in Figure 2) have found mul-
tiple applications [3]. First, inhibitors have been used to
elucidate the role of this enzyme in normal cell physiology
and also to mimic complex I de¢ciencies in order to study
mitochondrial diseases [4]. Second, the structure^activity
relationships (SAR) developed using inhibitors have pro-
vided important insights into the functional architecture of
this complicated enzyme system; furthermore, af¢nity
probes, constructed based upon these inhibitors, have pro-
ven valuable in identifying and characterizing the compo-
nents of complex I [5^7]. Third, NADH:ubiquinone oxi-
doreductase continues to be a preferred target for the
development of commercial insecticides and acaricides
[8]. Fourth, and more recently, it has been demonstrated
that inhibition of NADH:ubiquinone oxidoreductase
causes a corresponding reduction in the activity of orni-
thine decarboxylase (ODC), possibly through interruption
of signal transduction pathways [9]. ODC is responsible for
the biosynthesis of polyamine growth factors required for
normal cellular proliferation [10]. Since the overexpression
of ODC activity in tumor cells contributes to aberrant pro-
liferation, the ability of complex I inhibitors to reduce
ODC activity makes them potential candidates for devel-
opment as chemotherapeutic and/or chemopreventive
agents [11^13]. Moreover, there is increasing evidence
that modulation of complex I activity, through small mol-
ecules, can induce apoptosis thus further supporting the
potential of these inhibitors as anticancer agents [14].
The goal of this study was to identify novel lead com-
pounds through the screening of natural product-like com-
binatorial libraries. The motivation stemmed from the pre-
vious characterization of a family of naturally occurring
inhibitors isolated from Cube¤ resin, an extract of the roots
of Lonchocarpus utilis and Lonchocarpus urucu, which has
been used as a botanical insecticide for decades [15,16].
Figure 2. Representative natural and synthetic inhibitors of
NADH:ubiquinone oxidoreductase.
Figure 3. Selected natural product inhibitors (7^18) of
NADH:ubiquinone oxidoreductase isolated from Cubeè resin and
combinatorial library prototype (19).
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Separation of the constituents of this resin provided the
major components rotenone (1, Figure 2) and deguelin
(7, Figure 3) along with minor constituents, including de-
hydrodeguelin (8), oxadehydrodeguelin (9), lonchocarpu-
sone (10), 4-hydroxylonchocarpene (11), 4-hydroxy-3-
methoxylonchocarpene (12), stilbenes 13^15 and iso£a-
vones 16^18 (Figure 3) among others. Inspection of natural
products 7^18 revealed an interesting homology as all pos-
sessed a 2,2-dimethylbenzopyran motif linked to a terminal
aromatic ring through a variety of molecular bridges. De-
Scheme 1. General strategy for the solid phase combinatorial synthesis of natural product-like small molecules as potential inhibitors of
NADH:ubiquinone oxidoreductase. o-Prenylated phenols are cycloloaded onto a polystyrene-based selenenyl bromide resin to provide
immobilized benzopyran scaffolds which are functionalized and then coupled to a second aromatic unit, thereby affording bridged structures
23. Library members are released from the resin by oxidation of the selenium moiety to the corresponding selenoxide which undergoes
spontaneous syn-elimination to afford the desired benzopyran systems (19).
Scheme 2. Representative procedures for the solid phase synthesis of amides, esters, and thioesters. Reagents and conditions: (a) 0.5
equivalent (equiv) of selenenyl bromide resin (1.1 mmol/g), CH2Cl2, 25³C, 20 min; (b) 10.0 equiv of LiOH, THF:H2O (20:1), 50³C, 48 h;
(c) 10.0 equiv of (COCl)2, cat. DMF, CH2Cl2, 40³C, 2 h; (d) 10.0 equiv of piperazine, 1.0 equiv of 4-DMAP, CH2Cl2, 25³C, 12 h; (e) 5.0
equiv of 3,4-(OMe)2C6H3CH2XH (XNO, NH, S), 15.0 equiv of Et3N, 1.0 equiv of 4-DMAP, CH2Cl2, 25³C, 12 h; (f) 5.0 equiv of 3,4-
(OMe)2C6H3XH (XNO, NH, S), 15.0 equiv of Et3N, 1.0 equiv of 4-DMAP, CH2Cl2, 25³C, 12 h; (g) 5.0 equiv of 3,4-(OMe)2C6H3CO2H, 5.0
equiv of DCC, 1.0 equiv of 4-DMAP, CH2Cl2, 25³C, 24 h; (h) 6.0 equiv of H2O2, THF, 25³C, 20 min. DCC = 1,3-dicyclohexylcarbodiimide,
4-DMAP = 4-(dimethylamino)pyridine, DMF = N,N-dimethylformamide.
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Figure 4. Structures and IC50 values of screening library. The synthesis of individual members is described in the schemes and references
indicated.
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spite the diversity in these bridging units, all of the com-
pounds (7^18) inhibited complex I activity in in vitro as-
says [15,16]. Not surprisingly however, the potency of in-
hibition was strongly in£uenced by the orientation through
which the ‘bridge’ unit positioned the two ring systems
with respect to each other. For example, deguelin
(IC50 = 6.9 nM) is almost 500-fold more active than loncho-
carpusone (IC50 = 3300 nM). Given this effect, it was envi-
sioned that screening a benzopyran-based combinatorial
library wherein this ‘bridge’ unit was varied (i.e. structure
19, Figure 3) might lead to the identi¢cation of interesting
SAR, and potentially to new lead compounds in this series.
Notably, it was anticipated that these lead compounds,
synthesized through combinatorial chemistry, would be
more amenable (as compared to the parent natural prod-
ucts) to further synthetic modi¢cations as required for op-
timization of physical and pharmacological properties.
Results and discussion
First generation discovery library: the bridge region III
(compounds 25^76)
Having recently completed the synthesis of several large
benzopyran-based combinatorial libraries, we were well
positioned to assemble a suitable, ¢rst generation library
for evaluating this hypothesis [17^19]. Thus, a 52-mem-
bered library was selected for preliminary screening as
shown in Figure 4. Members were selected so as to simul-
taneously evaluate both the nature of the ‘bridge’ unit as
well as the importance of substituents on the terminal
aromatic ring system. Most members of this discovery li-
brary had been previously synthesized via a selenium-
based, solid phase strategy as outlined in Scheme 1. In
this approach, a series of ortho-prenylated phenols (20)
were cycloloaded (through a six-endo-trig electrophilic cyc-
lization reaction) onto a polystyrene-based selenenyl bro-
mide resin to afford resin-bound benzopyran scaffolds (21)
[20,21]. These scaffolds were then functionalized and
coupled with a second aromatic unit so as to create diverse
bridge types (23). Upon completion, structures of type 23
could be further derivatized if necessary, and then released
from the solid support by oxidation of the selenoether to
the corresponding selenoxide which could undergo facile
syn-elimination. The synthesis of compounds 25^28, 33,
35^41, 46^48, 50^54, 59^62, 64^66 and 73 (Figure 4) via
this solid phase route has been described previously [17^
21]. Representative procedures for the solid phase synthe-
sis of the remaining members of the described library are
illustrated in Scheme 2^4. All library members for biolog-
ical assay were chromatographically and spectroscopically
(1H-nuclear magnetic resonance) homogeneous.
As shown in Scheme 2, the ¢rst type of library members to
be constructed was a series of acyl derivatives. Initially,
ortho-prenylated phenol 77 was cycloloaded onto a selenen-
yl bromide resin [22] to afford benzopyran scaffold 78. The
methyl ester of 78 was then hydrolyzed (LiOH,
THF:H2O, 40‡C) to the corresponding carboxylic acid
which was converted to acid chloride 80 by treatment
with oxalyl chloride in the presence of catalytic amounts
of N,N-dimethylformamide (DMF). This acid chloride
then participated in three parallel reaction pathways. In
the ¢rst sequence, treatment of acid chloride 80 with pi-
perazine and 4-(dimethylamino)pyridine (4-DMAP) pro-
vided amide 81. The secondary amine of structure 81
was then coupled to 3,4-dimethoxybenzoic acid in the
presence of 1,3-dicyclohexylcarbodiimide (DCC) and 4-
DMAP to provide diamide 84 which was released from
the solid support by treatment with H2O2, giving diamide
45. In the second pathway, acid chloride 80 was treated (in
parallel) with a series of aryl nucleophiles including 3,4-
dimethoxyphenol, 3,4-dimethoxyaniline and 3,4-dimeth-
oxythiophenol to provide structures of type 83, which
upon oxidative cleavage afforded ester 30, amide 56 and
thioester 71, respectively. In the last pathway, acid chloride
80 was reacted with a series of benzylic nucleophiles in-
cluding 3,4-dimethoxybenzyl alcohol, 3,4-dimethoxybenzyl
amine and 4-methoxy-K-toluene thiol to provide structures
of type 82 which were oxidatively cleaved to afford ester
42, amide 31 and thioester 69, respectively. In addition to
the representative compounds shown here, this procedure
Scheme 3. Representative procedures for the solid phase
synthesis of ether (75), ester (29), and sulfonate (70) compounds.
Reagents and conditions: (a) 0.5 equiv of selenenyl bromide resin
(1.1 mmol/g), CH2Cl2, 25³C, 20 min; (b) 5.0 equiv of 3,4-
dimethoxybenzyl chloride, 5.0 equiv of K2CO3, DMF, 60³C, 12 h;
(c) 5.0 equiv of 3,4-dimethoxybenzoic acid, 5.0 equiv of DCC,
1.0 equiv of 4-DMAP, CH2Cl2, 25³C, 24 h; (d) 5.0 equiv of 3,4-
dimethoxybenzenesulfonyl chloride, 10.0 equiv of Et3N, 1.0 equiv
of 4-DMAP, CH2Cl2, 25³C, 12 h; (e) 6.0 equiv of H2O2, THF,
25³C, 20 min.
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was repeated in an analogous and parallel manner to pre-
pare compounds 32, 43^44, 49, 55, 57^58 and 68^69 (Fig-
ure 4).
As shown in Scheme 3, additional library members with
other types of bridging units were constructed from a phe-
nolic benzopyran system. Initially, resin-bound phenol 86
was prepared through the cycloloading of prenylated hy-
droquinone 85. Library members containing an ether-type
bridge were then constructed by alkylation of 86 with 3,4-
dimethoxylbenzyl chloride in the presence of K2CO3 fol-
lowed by oxidative cleavage to afford ether 75. Ester de-
rivatives were constructed by acylation of phenol 86 with
3,4-dimethoxybenzoic acid, DCC and 4-DMAP to afford,
after oxidative cleavage, ester 29. Lastly, sulfonate deriva-
tives were constructed by treatment of phenol 86 with 3,4-
dimethoxybenzenesulfonyl chloride, Et3N, and 4-DMAP
followed by oxidative cleavage to afford sulfonate 70. In
addition to the representative compounds shown here, this
procedure was also repeated in an analogous and parallel
manner to prepare compounds 63, 67, 74 and 76 (Figure 4).
As shown in Scheme 4, several sulfur-containing library
members were synthesized through a halogen^metal ex-
change reaction. Initially, prenylated bromophenol 88 was
cycloloaded onto the selenenyl bromide resin to give ben-
zopyran 89. Aryl bromide 89 was subjected to a halogen^
metal exchange reaction by treatment with n-BuLi at
378‡C and then warming to 0‡C over 2 h at which time
3,4-dimethoxyphenylisothiocyanate was added. Cleavage
of the supposed thioamide 90 by treatment with H2O2
unexpectedly afforded a separable mixture of thioamide
72 and thiazole 34 the latter being presumably formed as
a result of excess base present in the halogen^metal ex-
change reaction.
This primary library was screened for inhibitory potency
against NADH:ubiquinone oxidoreductase activity as de-
scribed below. This screening revealed several structure^
activity trends (summarized in Table 1 and discussed in
detail in the SAR section) which ultimately provided esters
42 and 55 as lead compounds. As described below, a series
of focused libraries were then synthesized using a combi-
nation of solid and solution phase chemistry in an attempt
to evaluate particular structural sub-regions (denoted I^IV
in Table 1) of the lead structure, thus allowing SAR to be
developed.
First focused library, aryl substituents, regions II and IV
(compounds 91^127)
The ¢rst of these follow-up libraries focused on regions II
and IV of the lead structure. Of particular interest was how
Scheme 4. Solid phase synthesis of thioamide (72) and thiazole
(34) systems. Reagents and conditions: (a) 0.5 equiv of selenenyl
bromide resin (1.1 mmol/g), CH2Cl2, 25³C, 20 min; (b) 10.0 equiv
of n-BuLi (1.6 M in hexanes), THF, 378C0³C, 2 h; then 10.0
equiv of 3,4-dimethoxyphenylisothiocyanate, THF, 378C25³C,
1 h; (c) 6.0 equiv of H2O2, THF, 25³C, 20 min.
Table 1
Summary of biological data from evaluation of ¢rst genera-
tion library and proposed lead structures.
Bridge IC50 (nM) Bridge IC50 (nM)
Chalcone 850^(s 3000) Alkyne 2300
Stilbene 2200^(s3000) Ester 55^(s 3000)
Coumarin 1900^(s3000) Amide 2300^(s3000)
Heterocycle 1100^(s3000) Ether 160^800
First generation lead compounds
Strategic regions for SAR optimization
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substituent patterns on these two aromatic systems would
effect inhibitory activity. Hence, a series of esters (91^127,
Figure 5) were synthesized in parallel on solid support
using an identical protocol to that described in Scheme
2. The aromatic building blocks employed contained a
variety of substituents including alkyl groups, halogens,
alkoxy groups, hydroxyl groups, alcohols and nitro groups
in order to assess both steric and electronic effects.
Second focused library, dimethylpyran modi¢cations,
region I (compounds 133^140)
The synthesis of the second of the follow-up libraries re-
lied upon solution phase chemistry and was designed so as
to evaluate how modi¢cations in the pyran ring system
might effect biological activity. Thus, as shown in Scheme
5, lead ester 55 was ¢rst resynthesized on a large scale from
4-hydroxymethyl benzoate 128 by initial O-alkylation with
3-chloro-3-methyl-1-butyne to give ether 129 [23]. Heating
of alkyne 129 in N,N-diethylaniline at 195‡C for 1 h in-
duced an aromatic Claisen rearrangement to provide ben-
zopyran 130 in quantitative yield [23]. The methyl ester of
130 was hydrolyzed (LiOH, THF:H2O, 40‡C, 12 h) to the
free acid 131 which was coupled to 3,4,5-trimethoxybenzyl
alcohol in the presence of DCC and 4-DMAP to furnish
ester 55. With the ester 55 in hand, several derivatization
reactions were employed to provide the series of pyran-
modi¢ed analogs 133^140. First, the ole¢n of ester 55
was dihydroxylated [24] (cat OsO4, NMO, t-
BuOH:THF:H2O, 25‡C, 6 h) to afford diol 133 which
was subsequently acetylated to diacetate 134 and reacted
with triphosgene to provide carbonate 135. In a second
event, ester 55 was treated [25] with NBS in the presence
Scheme 5. Solution phase synthesis of 3,4,5-trimethoxybenzyl
ester (55) and modi¢ed pyran analogs and their biological
activities. Reagents and conditions: (a) 2.0 equiv of 3-chloro-3-
methyl-1-butyne, 2.0 equiv of K2CO2, 1.7 equiv of KI, 0.02 equiv
of CuI, DMF, 65³C, 3 h, 88%; (b) Et2NPh, 195³C, 1 h, 100%;
(c) 2.0 equiv of LiOH, THF:H2O (10:1), 40³C, 12 h, 95%; (d) 1.1
equiv of 3,4,5-trimethoxybenzyl alcohol, 1.2 equiv of DCC, 0.1
equiv of 4-DMAP, CH2Cl2, 25³C, 12 h, 89%; (e) 0.1 equiv of
OsO4, 1.1 equiv of NMO, t-BuOH:THF:H2O (10:3:1), 25³C, 2 h,
71%; (f) 3.0 equiv of AcCl, 5.0 equiv of pyridine, CH2Cl2,
0C25³C, 1 h, 97%; (g) 5.0 equiv of triphosgene, 10.0 equiv of
pyridine, CH2Cl2, 0³C, 1 h, 80%; (h) 1.1 equiv of NBS,
DMSO:H2O (10:1), 0³C, 1 h, 80%; (i) 1.0 equiv of m-CPBA, 3.0
equiv of Na2CO3, CH2Cl2, 25³C, 24 h, 69%; (j) 0.2 equiv of 10%
Pd-C, H2, MeOH:hexane (1:1), 25³C, 6 h, 96%. DMSO = methyl
sulfoxide, NMO = 4-methylmorpholine N-oxide, NBS = N-
bromosuccinimide, m-CPBA = m-chloroperoxybenzoic acid.
Compounds 133^139 were synthesized and assayed as
racimates with the relative stereochemistry as shown.
Scheme 6. Synthesis of long chain 3,4-dimethoxyphenyl esters.
Reagents and conditions: (a) 1.5 equiv of 3,4-dihydropyran,
0.1 equiv of PPTS, CH2Cl2, 25³C, 2 h; (b) 2.0 equiv of 3,4-
dimethoxyphenol, 2.0 equiv of K2CO3, acetone, 40³C, 12 h;
(c) 1.2 equiv of TsOHWH2O, THF:MeOH (9:1), 25³C, 1 h; (d) 0.5
equiv of 80, 10.0 equiv of Et3N, 1.0 equiv of 4-DMAP, CH2Cl2,
25³C, 12 h; (e) 6.0 equiv of H2O2, THF, 25³C, 20 min.
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of H2O to provide a mixture of bromohydrins 136 and 137
as a result of partial bromination of the terminal aromatic
ring (i.e. structure 136). Bromohydrin 137 was subse-
quently acetylated (AcCl, pyridine, CH2Cl2, 25‡C, 1 h)
to afford acetate 138. Additionally, ester 55 was converted
to the corresponding epoxide 139 by treatment with m-
CPBA [26]. Finally, the ole¢n of ester 55 was saturated
by hydrogenation over 10% Pd^C to provide the corre-
sponding saturated pyran system 140.
Third focused library, the bridge region III
(compounds 146^179)
A ¢nal library in this series sought to further investigate
the nature of the bridge unit. Of particular interest was the
effect of length, structure and polarity of this bridge as
illustrated in Scheme 6^9. In order to access the relation-
ship between bridge length and biological activity, a set of
longer chain analogs 146^148 was synthesized as illustrated
in Scheme 6 where alcohols of type 141 were prepared by
alkylation of the corresponding bromoalcohols and then
coupled to resin-bound acid chloride 80 as previously de-
scribed. Subsequently, we sought to determine whether or
not an ester functionality was optimal as a bridge unit. This
was accomplished by the solution phase synthesis of vari-
Scheme 8. Solution phase synthesis of di£uoro- and
dichlorostyrene analogs 168 and 169. Reagents and conditions:
(a) 2.0 equiv of Ph3P, CCl4, 60³C, 15 h, 60%; (b) 5.0 equiv of
(EtO)2P(O)CHF2, 4.0 equiv of t-BuLi, DME, 378³C, 1 h; then
85³C, 15 h, 20%.
Scheme 7. Solution phase synthesis of 3,4,5-
trimethoxyphenylketone (158) and analogs thereof. Reagents and
conditions: (a) 1.2 equiv of 2-methyl-3-butyn-2-ol, 1.2 equiv of
tri£uoroacetic anhydride, 1.5 equiv of DBU, MeCN, 0³C, 6 h,
100%; (b) Et2NPh, 195³C, 1 h, 100%; (c) 3.0 equiv of BH3WTHF,
THF, 0C25³C, 2 h, 100%; (d) 1.1 equiv of Dess^Martin
periodinane, CH2Cl2, 25³C, 1 h, 90%; (e) 1.1 equiv of n-BuLi (1.6
M in hexanes), THF, 378³C, 15 min; then 2.0 equiv of 155, THF,
378³C, 15 min, 45%; (f) 5.0 equiv of MeI, 2.0 equiv of NaH,
THF, 0C25³C, 12 h, 85%; (g) 4.0 equiv of RONH2 (RNH, Me,
Bn), 5.0 equiv of K2CO3, EtOH, 75³C, 2 h, RNH: 52%, RNMe:
78%, RNBn: 81%; (h) 3.0 equiv of Lawesson's reagent, toluene,
100³C, 3 h, 42%; (i) 1.2 equiv of Tebbe reagent, THF,
340C0³C, 30 min, 88%; (j) 10.0 equiv of H4N2WH2O, 10.0 equiv
of KOH, di(ethylene glycol), 245³C, 6 h, 21%; (k) 0.2 equiv of
10% Pd-C, H2, MeOH:hexane (1:1), 25³C, 6 h; (l) 2.0 equiv of
10% Pd-C, H2, MeOH, 25³C, 12 h.
6
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ous other linking units, including ketones, oximes, thioke-
tones, alkyl chains, thioethers and sulfones as shown in
Schemes 7^9. As illustrated in Scheme 7, various keto
analogs and their derivatives were constructed starting
from 4-bromophenol 149. Following the procedure of
Ding, 4-bromophenol (149) was alkylated with the in situ
generated tri£ate of 2-methyl-3-butyn-2-ol to afford 150,
which was heated to 195‡C in N,N-dimethylaniline induc-
ing an aromatic Claisen rearrangement and providing ben-
zopyran 151 in quantitative yield [27]. Subsequent treat-
ment of 151 with n-BuLi afforded aryl lithium 152, which
was immediately quenched by addition of aldehyde 155
(synthesized from phenylacetic acid 153, as indicated in
Scheme 7) to provide benzyl alcohol 156. Dess^Martin
periodinane oxidation of alcohol 156 afforded ketone 158.
Incidentally, the methyl ether analog of alcohol 156, com-
pound 157, was also synthesized from alcohol 156 via al-
kylation with MeI in the presence of NaH. With ketone
158 available, a series of modi¢ed keto-analogs were then
constructed. Thus, oximes 159^161 were prepared by con-
densation of ketone 158 with the appropriate hydroxy or
alkoxy amines in the presence of K2CO3. Thioketone 162
was prepared by reaction of ketone 158 with Lawesson’s
reagent in toluene at 100‡C for 3 h, whereas the corre-
sponding ole¢n analog 163 was constructed by treatment
of ketone 158 with Tebbe reagent. Wolf^Kishner reduction
of 158 (H4N2, KOH, W) afforded the alkyl variant 164, while
hydrogenation over 10% Pd^C provided the saturated ver-
sion (i.e. 165) of ketone 158 as well as of analogs 163 and
164 (i.e. 167 and 166, respectively). Additional variations of
ketone 158 were also constructed to address the impor-
tance of tether length and bridge substitution. These ana-
logs were synthesized via an analogous protocol to that
shown in Scheme 7 and their structures (170^174) are il-
lustrated in Figure 5.
Several halogenated derivatives of styrene 163 were also
prepared as illustrated in Scheme 8. Hence, ketone 165
was treated with Ph3P in CCl4 at 60‡C to afford di-
chloro-analog 168 [28]. Additionally, ketone 165 was added
to a solution of diethyl(di£uoromethyl)phosphonate and
t-BuLi in DME at 378‡C and then warmed to 25‡C,
Scheme 9. Synthesis of 3,4,5-trimethoxyphenylthioether 178 and
3,4,5-trimethoxyphenylsulfone 179. Reagents and conditions:
(a) 1.0 equiv of 3,4,5-trimethoxybenzyl chloride, 3.0 equiv of
K2CO3, 0.2 equiv of TBAI, DMF, 25³C, 2 h, 74%; (b) 2.0 equiv of
3-chloro-3-methyl-1-butyne, 2.0 equiv of K2CO3, 1.7 equiv of KI,
0.02 equiv of CuI, DMF, 65³C, 3 h, 40%; (c) Et2NPh, 195³C, 1 h,
100%; (d) 2.5 equiv of OXONE, 2.5 equiv of NaHCO3, THF:H2O
(2:1), 25%. TBAI = tetrabutylammonium iodide.
Figure 6. Lead compounds (and their IC50 values) selected for evaluation in cell-based assays.
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and ¢nally to 85‡C to ultimately afford di£uoro-analog 169
[29].
A ¢nal set of compounds for addressing the nature of
the bridge unit was prepared as illustrated in Scheme 9
in an attempt to optimize the activity observed for ether
75 during screening of the ¢rst generation library. The
thioether variant of this analog was prepared from 4-mer-
captophenol (175) by selective S-alkylation with 3,4,5-tri-
methoxybenzyl chloride and K2CO3 to provide thioether
176 [30]. Subsequent O-alkylation was effected with 3-
chloro-3-methyl-1-butyne to give alkynyl ether 177. Heat-
ing of alkyne 177 in N,N-diethylaniline at 195‡C for 1 h
induced an aromatic Claisen rearrangement furnishing ben-
zopyran 178 in quantitative yield. A portion of thioether
178 was then oxidized with OXONE0 to afford the corre-
sponding sulfone 179.
SAR
SAR optimization was carried out on each of the four re-
gions (I^IV) of interest guided by the inhibitory potency
for NADH:ubiquinone oxidoreductase activity in vitro us-
ing bovine heart electron transport particles (see Singer
[31] for details).
The original library emphasizing bridge region III gave the
IC50 values for 25^76 indicated in Figure 4 and the SAR
summarized in Table 1. Compounds containing a conju-
gated and/or rigid bridging unit (i.e. chalcones, stilbenes,
coumarins, heterocycles or alkynes) exhibited low activity
(IC50s 1000 nM) similar to those for most of the benzo-
pyran-containing natural products (11^15, Figure 3). More
interestingly, methylenes in the bridge unit, for greater
conformational £exibility, resulted in higher activity depen-
dent on the substituent pattern on the terminal aromatic
ring, i.e. 220 nM IC50 for 3,4-dimethoxybenzyl esters 42
and 55 nM IC50 for 3,4,5-trimethoxybenzyl ester 55, the
most potent inhibitor in the screening library. The corre-
sponding amides (31 and 44, Figure 4), presumably more
polar than their ester counterparts, were signi¢cantly less
active (40- and 10-fold, respectively), suggesting the pos-
sible importance of lipophilicity at region III.
The ¢rst of the focused libraries (91^127, Figure 5) exam-
Table 2
Selected data for growth inhibition (GI50) of compounds 55, 158, 165 and 178 in NCI cancer cell lines
a.
Cancer cell type GI50 (nM)
165 158 178 55 Averageb
Leukemia
HL-60 340 14 840 1 810 750
K-562 730 1 540 5 090 2 900 2 800
MOLT-4 96 340 1 230 6 800 2 560
RPMI-8226 940 3 040 2 660 4 760 2 850
NSC lung
EKVX 66 680 3 930 8 620 3 320
HOP-62 830 280 6 690 31 300 9 780
NCI-H226 330 1 090 5 560 15 500 5 620
NCI-H322M 180 560 2 210 49 600 13 100
Colon
HCT-116 740 1 370 4 850 7 930 3 720
HCT-15 440 12 600 3 970 8 940 6 490
SW-620 660 23 300 6 400 21 300 12 900
CNS
SF-295 690 23 100 4 580 23 300 12 900
SNB-19 660 17 100 6 110 11 700 8 890
U-251 210 430 2 580 14 300 4 380
Melanoma
LOX IMVI 180 19 700 3 050 9 100 8 010
MALME-3M 320 13 400 2 370 7 700 5 950
SK-MEL-5 490 1 910 5 160 3 200 2 690
UACC-257 210 780 3 010 14 500 4 630
Breast
MCF-7 3 080 880 6 570 9 100 4 910
NCI/ADR-RES 670 2 500 2 350 6 800 3 080
HS 578T 600 860 7 400 25 000 8 470
MDA-MB-435 2 790 37 200 7 110 14 800 15 500
Averagec 690 7 380 4 300 13 600
aAssays were performed by the Developmental Therapeutics Program of the National Cancer Institute, USA. The compounds were pro-
vided as DMSO solutions and evaluated for their in vitro cytostatic properties against 60 human cell lines using the NCI standard protocol.
bAverage GI50 value for compounds 55, 158, 165 and 178 in a particular cell line.
cAverage GI50 value for a single compound in all cell lines.
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ined the substituent patterns for aromatic regions II and
IV. Somewhat surprisingly, only esters 110 (IC50 = 44 nM)
and 120 (IC50 = 49 nM) exhibited marginally improved ac-
tivity over the original 3,4,5-trimethoxybenzyl ester 55
(IC50 = 55 nM). Varying substituents on the aromatic ben-
zopyran ring only moderately in£uenced activity, e.g. in-
troducing a halogen at R1 (42C104; 55C112) or a hydrox-
yl group at R2 (55C110). A bulky substituent of the
Figure 5. Summary of structure activity trends observed for benzopyran-based inhibitors of NADH:ubiquinone oxidoreductase.
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oxygen at R4 (42C121; 55C122) resulted in only slightly
diminished inhibitory activity implying the greater impor-
tance of electronic rather than steric factors at this position.
More generally, the 3,4,5-trimethoxyphenyl substituent is
at or near the optimum for region IV.
The second focused library considered modi¢cations of the
pyran ring system (Figure 5). Introduction of a polar func-
tionality on the pyran ring (i.e. 133 and 134) signi¢cantly
compromised activity, and less polar substituents (i.e. 135^
139) afforded no improvements. However, conversion to its
saturated counterpart (55C140) resulted in a compound
which retained potent biological activity (IC50 = 53 nM)
yet was presumably metabolically more stable owing to
the removal of the oxidatively sensitive pyran ole¢n.
A ¢nal focused library reexamined the bridging unit (re-
gion III) with keto-analogs revealing several interesting
trends (Figure 5). First, ketone 158 was more active than
the original ester lead with an IC50 value of 39 nM. Alcohol
156, ether 157, oximes 159^161, thioketone 162, and com-
pound 164 were signi¢cantly less active than ketone 158.
Removal of the pyran ole¢n of ketone 158 via hydrogena-
tion provided compound 165 which was almost twice as
active as the parent ole¢n with an IC50 value of 24 nM.
Intriguingly, conversion of the ketone to the corresponding
ole¢n also increased activity as demonstrated for com-
pound 163 (IC50 = 19 nM) and its saturated pyran counter-
part 167 (IC50 = 18 nM). Substitution of the ole¢n protons
with halogens (i.e. structures 168 and 169) resulted in di-
chloro- and di£uoro-analogs with reduced activity (IC50
values 2700 and 48 nM, respectively). On a separate
note, thioether 178 was quite active with an IC50 of 43
nM, whereas the more polar sulfone 179 was inactive.
The overall results summarized in Figure 5 prompted se-
lection of 55, 158, 163, 165, 167 and 178 (Figure 6) for
further biological testing. Despite their structural simplic-
ity, the inhibitory activity of these compounds approached
that for the most potent natural product in this series,
namely deguelin (7, Figure 3) with an IC50 value of 6.9
nM. Moreover, unlike the structurally complex deguelin,
these lead compounds were simple to construct and thus
could be readily modi¢ed to improve pharmacological
properties, solubility or biostability.
The identi¢ed lead compounds were evaluated in several
cell-based assays. The ¢rst involved determination of the
cytotoxic concentrations (LC50 values) in MCF-7 human
epithelial breast cancer cells using the MTT assay [16].
The six compounds tested showed low cytotoxicity in
the MCF-7 cells (LC50s 30000 nM). Secondly, com-
pounds 55, 158, 165 and 178 were also evaluated in the
NCI 60-cell cancer panel for the concentration leading to
50% growth inhibition (GI50; see representative examples
in Table 2) [32]. Moderate to good activity was observed in
growth inhibition in various cell lines. The leukemia cells
are generally the most sensitive (GI50 from 750 to 2850
Figure 7. Molecular modeling of deguelin (7), ester 55, and ketone 158.
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nM) and the CNS cells the least sensitive (GI50 from 4380
to 12900 nM) to these compounds and the overall potency
order is 165s 178s 158s 55. The combination of rather
potent growth inhibition and possibly low cytotoxicity
makes these compounds interesting lead structures as po-
tential chemopreventive/chemotherapeutic agents.
Rationalization of SAR by molecular modeling
In an effort to better understand the molecular basis for
the potent inhibitory activity exhibited by several of these
compounds, molecular modeling studies were undertaken.
Speci¢cally, we hoped to compare the three-dimensional
orientation of these leads to that of the structurally more
complex natural product deguelin [7] (7, Figure 3) which
remains the most potent compound in the benzopyran ser-
ies. As illustrated in Figure 7, the semi-rigid structure of
deguelin (7) was ¢rst minimized with molecular mechanics
calculations (Insight II, CFF93 force ¢eld [33]) which pro-
vided its lowest energy conformation as the skewed struc-
ture denoted as B in Figure 7. Subsequently, ester 55
(Figure 6) and ketone 158 (Figure 6) were also minimized
with the two lowest energy levels of each presented in
Figure 7 (i.e. structures A and D for ester 55 and structures
C and F for ketone 158). Comparison of these minimized
structures revealed that the second lowest energy confor-
mation of ester 55 (structure D) and the lowest energy
conformation of ketone 158 (structure C) resembled quite
closely the bent con¢guration of deguelin 7 (structure B).
In fact, the overlay of the lowest energy conformations of
deguelin 7 (B) and ketone 158 (C), presented in diagram E
(Figure 7), illustrate a strong homology between the two
structures. The fact that the lowest energy con¢guration of
ketone 158 best matched deguelin, whereas the less popu-
lated second lowest energy con¢guration of ester 55
matched deguelin was consistent with the fact that ketone
158 with an IC50 value of 39 nM was more potent than
ester 55 which possessed an IC50 value of 55 nM.
Signi¢cance
Herein we have described how synthetic combinatorial li-
braries, modeled after natural products, can be utilized to
discover novel and structurally simple lead compounds as
inhibitors of the enzyme NADH:ubiquinone oxidoreduc-
tase (the current structure activity relationships comple-
ment previous work in the rotenone series; for a discussion
see [34,35]). After discovery, several of these lead inhibi-
tors were optimized through the synthesis of focused libra-
ries which re¢ned speci¢c sub-units of the lead com-
pounds. Ultimately a collection of benzopyran-based
inhibitors with IC50 values 18^55 nM were identi¢ed. Sev-
eral of these inhibitors were then evaluated in cell-based
assays to evaluate their cytotoxic and cytostatic properties.
Interestingly, while most of the compounds were relatively
non-cytotoxic, several exhibit potent cytostatic activities
across a variety of cancer types and cell lines. The ability
of these small molecules to inhibit cancer cell growth, per-
haps mediated by the ability to interrupt ODC activity,
makes them potential candidates for further development
as chemopreventive/chemotherapeutic agents. Further
evaluation of these compounds is in progress along with
the application of similar natural product-like combinatorial
libraries to the discovery of lead compounds in other bio-
logical systems.
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